Table 1: Baseline maternal characteristics by dose-delivery interval (n = 659).
|
Maternal characteristics |
DDI category 1 < 155 mins (n = 166) |
DDI category 2 155-314 mins (n = 164) |
DDI category 3 314-526.5 mins (n = 165) |
DDI category 4 > 526.5 mins (n = 164) |
P-value |
|
Maternal age (years), median (IQR) |
29 (25-33) |
29 (25-33) |
29 (25-32) |
28 (26-32) |
0.495 |
|
Parity, n (%) |
1 (0-2) |
1 (0-1) |
0 (0-0) |
0 (0-0) |
< 0.001 |
|
Gravidity, n (%) |
2 (1-3) |
2 (1-3) |
1 (1-2) |
1 (1-2) |
< 0.001 |
|
Maternal country of birth, n (%) |
|
|
|
|
0.287 |
|
Oceania |
83 (50.0%) |
73 (44.5%) |
74 (44.8%) |
78 (47.6%) |
|
|
Asia |
52 (31.3%) |
60 (36.6%) |
59 (35.8%) |
61 (37.2%) |
|
|
Middle East |
22 (13.3%) |
24 (14.6%) |
23 (13.9%) |
13 (7.9%) |
|
|
Eastern Europe |
5 (3.0%) |
2 (1.2%) |
2 (1.2%) |
5 (3.0%) |
|
|
European Union |
0 (0.0%) |
0 (0.0%) |
3 (1.8%) |
2 (1.2%) |
|
|
Africa |
3 (1.8%) |
3 (1.8%) |
0 (0.0%) |
4 (2.4%) |
|
|
The Caribbean |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
1 (0.6%) |
|
|
North American |
1 (0.6%) |
0 (0.0%) |
1 (0.6%) |
0 (0.0%) |
|
|
Not stated |
0 (0.0%) |
2 (1.2%) |
3 (1.8%) |
0 (0.0%) |
|
|
Mode of delivery, n (%) |
|
|
|
|
< 0.001 |
|
Normal vaginal delivery |
140 (84.3%) |
103 (62.8%) |
67 (40.6%) |
40 (24.4%) |
|
|
Caesarean |
13 (7.8%) |
33 (20.1%) |
48 (29.1%) |
69 (42.1%) |
|
|
Instrumental delivery |
13 (7.8%) |
28 (17.1%) |
50 (30.3%) |
55 (33.5%) |
|
|
Epidural, n (%) |
|
|
|
|
< 0.001 |
|
No |
156 (93.9%) |
124 (76.5%) |
67 (40.9%) |
35 (21.3%) |
|
|
Yes |
10 (6.1%) |
38 (23.5%) |
97 (59.1%) |
129 (78.7%) |
|
|
Spinal anaesthetic, n (%) |
|
|
|
|
0.184 |
|
No |
165 (99.4%) |
156 (96.3%) |
159 (97.0%) |
161 (98.2%) |
|
|
Yes |
1 (0.6%) |
6 (3.7%) |
5 (3.0%) |
3 (1.8%) |
|
|
Fentanyl PCA, n (%) |
|
|
|
|
0.182 |
|
No |
166 (100.0%) |
162 (100.0%) |
164 (100.0%) |
162 (98.8%) |
|
|
Yes |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
2 (1.2%) |
|
|
IM pethidine, n (%) |
|
|
|
|
1.000 |
|
No |
165 (99.4%) |
162 (100.0%) |
164 (100.0%) |
164 (100.0%) |
|
|
Yes |
1 (0.6%) |
0 (0.0%) |
0 (0.0%) |
0 (0.0%) |
|
|
Route of morphine administration, n (%) |
|
|
|
|
0.816 |
|
Intramuscular (IM) |
145 (87.3%) |
140 (85.4%) |
140 (84.8%) |
150 (91.5%) |
|
|
Intravenous (IV) |
3 (1.8%) |
1 (0.6%) |
3 (1.8%) |
4 (2.4%) |
|
|
Subcutaneous (SC) |
6 (3.6%) |
7 (4.3%) |
4 (2.4%) |
4 (2.4%) |
|
|
Total amount of morphine, median (IQR) |
10 (10-10) |
10 (10-10) |
10 (10-10) |
10 (10-10) |
0.051 |